anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a mucosal immunopotentiator comprising an unconventional slightly digestible saccharide as an active ingredient.  &lt;P&gt;SOLUTION: The new mucosal immunopotentiator comprises a cyclofructan which is a cyclic inulooligosaccharide composed by binding fructose molecules into a cyclic form with β-2,1 bonds. The mucosal immunopotentiator has high general-purpose properties and widely applicable to objects of application to the oral cavity such as a food and drink or a medicine. When the mucosal immunopotentiator is ingested, the production of secretory type IgA is induced in the intestinal canal mucous membrane. Immunological functions of a biophylactic system can be maintained and improved by an increase in secretory type IgA content in feces. Thereby, the mucosal immunopotentiator can be connected to prophylaxis of various diseases such as infectious diseases, inflammatory bowel diseases or allergic diseases caused by lowering of mucosal immunological functions.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The compounds with a general formula Ia, where R1 and R2 mean hydrogen, C1-7 alkyl or C2-7 means hydrogen, halogen, C1-7 alkyl. The symbol Q&#39; means C5-11 alkylene with 5 carbon atoms at least between two free valences, or it means C4-11 alkenylene with 4 carbon atoms at least between two free valences and Y and Y&#39; mean a direct bond or a group -CH2-, -CH2CH2-, -CH=CH- or -C­C-. The group called R1R2-Q&#39;-Q- is bound in the position 3 or 4 closed to the ring A. The symbol R means, this ring is not substituted or it is substituted by the halogen, by the group of CF3, CN, NO2, C1-7 alkyl and/or C1-7 alkooxyl once at least, however the symbols Y and Y&#39; do not mean a direct bound simultaneously, in the case the symbol Q&#39; means C5 alkylene and R1 and R2 mean C2-7 alkyl simultaneously and also their additional salts with acids. These salts can have a pharmaceutical utilisation. This patent also describes the way of the production closed to the compounds with the formula Ia together with an application of them in the production of means with anti-fungal activities.
The invention relates to an auscultation instrument which can be used for real-time remote medical consultation and remote medical monitoring. A digital stethoscope includes a device for detecting analog acoustic signals from a patient, and a data processing system implemented by a secure encrypted web application on a portable computing device of the patient and/or physician to which headphones are connected. Software processing of the data is performed on the doctor and/or patient&#39;s device. Information about the patient is acquired and stored. The digital data is converted into an audio signal. The audio signal is displayed in the form of an audio map in a window of a doctor&#39;s web browser. The audio signal is processed based on the user settings. The processed audio signal is output to the headphones. Data about the applied digital filter is stored. The result is an improved quality and speed of signal processing while reducing energy consumption and allowing safe auscultation of patients suffering from highly contagious diseases such as new coronaries. The stethoscope can be used simultaneously with a plurality of wireless headsets on a plurality of user devices, taking into account the individual psycho-acoustic characteristics of the users and the different psycho-acoustic perceptions of sound by different specialists.
PURPOSE:To obtain a liquid agent for a hardened calcium phosphate material, capable of imparting excellent spreadability and formability to a kneaded paste and useful as a medical or dental cement material or a bone anaplerotic material by dissolving a specific amount of a hyaluronic acid compound in an aqueous solution of an acid. CONSTITUTION:The objective liquid agent is prepared by dissolving a hyaluronic acid compound (e.g. sodium hyaluronate) in an aqueous solution of an acid (e.g. phosphoric acid or citric acid) in an amount to give a liquid having a viscosity of &gt;=15 cp, preferably 500 to 10,000cp at room temperature. A hardened calcium phosphate having high strength and harmless to biotissue can be produced by mixing the liquid agent to a powdery agent containing tricalcium alpha-phosphate and/or tetracalcium phosphate as essential components. The progress of the hardening reaction can be retarded by the addition of at least one kind of compound selected from monosaccharides, oligosaccharides, sugar alcohols and polyhydric alcohols to the liquid agent.
The invention comprises compounds of the formula: &lt;FORM:0854631/IV(b)/1&gt; (wherein R is an aryl radical which may be substituted by one or more halogen atoms or alkyl groups, R1 is a hydroxy, alkoxy, dialkylaminoalkoxy, mercapto or alkylmercapto group and R2 is hydrogen, an alkyl radical or, if R1 is a free hydroxy or mercapto group, also a free hydroxy or mercapto group respectively, the alkyl radicals each containing at most 7 carbon atoms) including tautomers thereof; and salts thereof.  The compounds containing free hydroxy groups may be prepared by reacting a 5-unsubstituted 2-aryl-3-amino-pyrazole-4-carboxylic acid or an ester or the amide thereof with formamide or urea or an alkane carboxamide, or the amide of the pyrazole carboxylic acid with an alkane carboxylic acid or reactive derivative thereof. p  Hydroxy groups in the resulting products may subsequently be replaced by chlorine atoms and the chloro compounds reacted with a metal alcoholate or mercaptide or a metal hydrosulphide or thiourea to introduce alkoxy, mercapto or alkylmercapto groups, or the free hydroxy groups may be substituted directly, for example by reaction with alkyl or dialkylaminoalkyl halides.  Metal salts of the free hydroxy or mercapto compounds may be made, and basic compounds may be converted to salts with inorganic or organic acids, an extensive list of which is given.  Examples describe the preparation of 1-phenyl-4-hydroxy-pyrazolo-(3 : 4-d)-pyrimidine and the corresponding 4-methoxy, 4-mercapto, 4-dimethylaminoethoxy and 4 : 6-dihydroxy compounds and of 1-phenyl-4-hydroxy-6-methyl-and 1-(p-chlorophenyl)-4-hydroxy-pyrazolo-(3 : 4-d)-pyrimidines. hydrochloride of one of the products is also described. Specifications 854,632, 854,633 and 854,634 are referred to.ALSO:Pharmaceutical preparations comprise compounds of the formula:  &lt;FORM:0854631/VI/1&gt; (wherein R is an aryl radical which may be substituted by one or more halogen atoms or alkyl groups, R1 is a hydroxy, alkoxy, dialkylaminoalkoxy, mercapto or alkylmercapto group and R2 is hydrogen, an alkyl radical or, if R1 is a free hydroxy or mercapto group, also a free hydroxy or mercapto group respectively, the alkyl radicals each containing at most 7 carbon atoms) including tautomers thereof, and salts thereof, in admixture with conventional pharmaceutical inorganic or organic excipients suitable for enteral, parenteral or topical administration in forms such as tablets, dragees, salves, creams, solutions, suspensions or emulsions.  They may contain preserving, stabilizing, or emulsifying, wetting agents and other therapeutically valuable substances.  Specified salts are hydrohalides, sulphates, nitrates, perchlorates, phosphates, formates, acetates, propionates, lactates, oxalates, succinates, malates, tartrates, citrates, ascorbates, benzoates, salicylates, p-aminosalicylates and methane-, ethane-, hydroxyethane-, toluene- and naphthalene-sulphonates.  Specifications 854,632, 854,633 and 854,634 are referred to.
This invention is the preparation method of temperature-sensitive polyisopropyl acrylamide-polyarginine. It also belongs to temperature sensitive transgenetic vector preparation technology. The procedure is as followings: dissolve polyisopropyl acrylamide in tetrahydrofuran, add the initiating agent 4, 4-tetrahydrofuran (cyano valerianic acid), heat in water bath, wash the product within nitrogen production, dissolve with deionized water, get polyisopropyl acrylamide with N-end terminated by carboxyl after dialysis and freezing drying.then dissolve it in HCl/N,N,N&#39;,N&#39;tetramethylethylenediamine buffer. Add polyarginine and carbodiimide, agitate while reacting, centrifuge at different temperatures. Get polyisopropyl acrylamide-polyarginine after freezing-drying. This invention is advantageous in simplified-manipulation and mild reaction temperature. The product could be used as transgenetic vector to regulate the transportation and expression of DNA.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a menstrual pain relieving agent which is mainly orally ingested to relieve pain accompanying menstruation and improve menstrual molimen peculiar to women, thereby capable of obtaining improvement effect of Quality of Life (QOL).  &lt;P&gt;SOLUTION: There are provided a menstrual pain relieving agent and an oral menstrual pain relieving agent each containing an iron-bound type lactoferrin as an active ingredient. There is provided food and drink in which any of the relieving agents is blended. There is also provided a method of relieving menstrual pain by ingesting 10-6,000 mg of an iron-bound type lactoferrin per day. These relieve pain accompanying menstruation and improve menstrual molimen peculiar to women, thereby capable of obtaining improvement effect of QOL.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair-developing, growing and nourishing method using an extract of Fomes yucatensis, and to provide a new medicament usable therefor, and a cosmetic.  &lt;P&gt;SOLUTION: The medicament or the cosmetic containing the extract of the Fomes yucatensis is produced. The Fomes yucatensis (Sou-ou) used in the extract of the Fomes yucatensis can be either one of the wild one or the one sold at a general grocery store. The growth of the hair is promoted by administering the Fomes yucatensis to human beings or vertebrates except the human beings. The hair growth promotor is useful for promotion of hair-growth and hair-nourishment, prevention of depilation, promotion of hair restoration or promotion of hair development.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
There is provided a diagnostic tool for use in diagnosing diseases, the tool having a detector for detecting the presence of an array of markers indicative of disease. Also provided is a combination of markers for disease, the combination including at least two markers of the disease. A method of choosing such combinations of markers for a given disease as well as a method for detecting a combination of markers for diagnosing the presence of a disease state or determining a disease stage is also provided. The method includes selectively biopanning sera obtained from a patient to obtain cDNA clones to array for analysis and determining if the markers are present among the cDNA clones present in the disease. Epitopes found using this method are also provided as well as a database incorporating these epitopes. A biochip for detecting the presence of a disease marker in a patient&#39;s sera is provided, wherein the biochip has a detector contained within the biochip for detecting disease markers in a patient&#39;s sera.
NEW MATERIAL:A compound expressed by formula I (formula II represents single bond or double bond, provided that all the formulas II represent single bond or formula II between the positions 2 and 2&#39; and all the other formula II represent double bond or formula II between the positions 2 and 3 represents single bond and all the other formulas II represent double bond). EXAMPLE:2,6,6,9-Tetramethyl-1-methoxy-cycloundecane. USE:A perfume substance or synthetic intermediate therefor which is a compound having strong woody, amberlike or balsamlike fragrance with improved lasting quality and useful in the filed of perfume industry and used also as an active ingredient for flavoring and improving agent for foods and drinks (including tasty materials), cosmetics, health, hygiene, medicines, etc. PREPARATION:A compound expressed by formula III is reacted with an alcoholate forming agent, e.g. NaH, etc., in an organic solvent and the resultant product is further reacted with a methylating agent, e.g. dimethyl sulfate, etc., to afford the aimed compound expressed by formula I (all the formulas II are single bond).
PURPOSE:To obtain the objective composition for oral cavity application exhibiting specific antibacterial action against Streptococcus mutans, free from influence upon other normally existing bacteria and effective in preventing the formation of dental plaque and dental caries by using tormentic acid or its salt as an active component. CONSTITUTION:The objective composition contains tormentic acid or its salt which is a pentacyclic acidic triterpene compound existing in nature e.g., in a plant of genus Comanthosphace, family Labiatae, etc. The compound of formula can be used as a composition for oral cavity application by mixing with a proper excipient, adjuvant, etc., and forming into a drug or by adding to conventional food. The preferable form of the composition is dentifrice, gargle, liquid ointment, troche, chewing gum, candy, drink, etc. The concentration of the compound of formula in the composition in use is preferably &gt;=0.005(w/v)%. The composition is especially useful for the prevention of dental caries of infant.
PROBLEM TO BE SOLVED: To obtain the subject preparation useful as an antiallergic medicine exhibiting an antihistamic action in the form of a dry syrup not discolored with tap water by adding a specific compound. SOLUTION: This mequitazine preparation is obtained by adding &lt;=3 pts.wt. of citric acid or succinic acid to mequitazine and subsequently processing the mixture into a dry syrup. The citric acid or succinic acid includes their anhydrides and salts, such as citric anhydride, citric acid hydrate, sodium citrate, potassium citrate, succinic anhydride, sodium succinate and potassium succinate. One of the compounds may be used, or two or more of the compounds may simultaneously be used. The dry syrup is obtained by adding the mixture of the mequitazine with additives (a sugar, a flavor, a sweetener, etc.), to the 50% ethanol solution of the citric acid or succinic acid, kneading the mixture and subsequently drying the kneaded product.
Animal, vegetable, or mineral oils are rendered less viscous, and suitable for use on the skin &amp;c. by adding up to 10 per cent of an essential oil.  Oils specified are coco nut, cod liver, paraffin or sulphurized oil, e.g. schist oil, mixed with lemon or lavender oil. The essential oil or the final composition may be treated in an atmosphere of nitrogen with ultra-violet rays, whereby the cloudines which may appear on mixing the oils is prevented or dispersed.ALSO:Animal, vegetable or mineral oils are rendered less viscous and suitable for use on the skin by adding up to 10 per cent of an essential oil.  Oils specified are coco nut, cod liver, paraffin or sulphurized oil, e.g. schist oil (ichthyol), mixed with lemon or lavender oil.  The essential oil or the final composition may be treated in an atmosphere of nitrogen with ultra-violet rays, whereby the cloudiness which may appear on mixing the oils is prevented or dispersed.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a new salt of monatin expected as a sweentener and an organic amine and its crystal and to provide a new method for resolving a stereoisomer of monatin.  &lt;P&gt;SOLUTION: The salt of monatin and an organic amine component such as an amino acid, an amino-alcohol, a dipeptide ester, etc., is provided as the new salt of monatin. The salt of monatin and an amino acid, a dipeptide ester, etc., is usable as a sweetening substance, its crystal is stable, has high sweetness and is expected to be a sweetener, its component and a sweetness providing component for food and beverage. The method for producing a stereoisomer of monatin comprises forming crystal of a salt of the stereoisomer mixture of monatin and an organic amine and using difference in crystallinity and solubility. A product such as a sweetener using monatin or food and beverage provided with sweetness is obtained by a method for producing a high-purity stereoisomer of monatin.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PCT No. PCT/US87/00191 Sec. 371 Date Jul. 23, 1987 Sec. 102(e) Date Jul. 23, 1987 PCT Filed Jan. 29, 1987 PCT Pub. No. WO87/04594 PCT Pub. Date Aug. 13, 1987.This invention provides compositions comprising a compound having the structural formula  &lt;IMAGE&gt;  wherein each X, Y and Z may represent oxygen, sulfur or two hydrogen atoms, provided however that, when Z represents two hydrogen atoms, both X and Y represent oxygen or sulfur and when Z represents oxygen or sulfur at least one of X and Y must represent oxygen or sulfur; m is 2-6; R&#39; is H or a lower alkyl group having 1-4 carbon atoms; n is 0-17 and R is -CH3,  &lt;IMAGE&gt;  wherein R&#39;&#39; is H or halogen. The invention also provides compositions comprising a physiologically-active agent and the hereinabove recited 1-substituted azacycloalkane compound in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal. Other compositions of 1-substituted azacycloalkanes and their uses relate to an improved method of dyeing fibers, improved delivery of plant nutrients, improved plant pest control, improved delivery of plant growth regulations, improved acid-catalyzed conversion of a reactant into a reaction product and an improved insect repellant.
The present disclosure relates to a method and system for diagnosing coronavirus disease COVID-19 using artificial intelligence. Embodiments of the present disclosure provide methods and systems for detecting COVID-19 from images of a patient&#39;s lungs. The exemplary system may include a communication interface configured to receive a lung image of a lung of a patient acquired by an image acquisition device. The system may further include at least one processor configured to determine a region of interest including the lung from the lung image, and apply a codv-19 detection network to the region of interest to determine a condition of the lung. The COVID-19 detection network is a multi-class classification learning network that labels regions of interest as one of COVID-19, non-COVID-19 pneumonia, non-pneumonia abnormalities, or normality. The at least one processor is further configured to provide a diagnostic output based on the determined condition of the lung.
PURPOSE:To obtain a cosmetic providing a product having color tone corresponding to purpose and wide color tone, having excellent spread and smooth touch, free from make-up collapse, by adsorbing high-purity carthamin on cellulose acetate powder to give colored powder and adding the colored powder to a cosmetic. CONSTITUTION:High-purity carthamin having &gt;=E(0.0006%/1cm)=0.10 is dissolved in an alkali aqueous solution, the solution is blended with cellulose acetate powder having 0.5-100mu average particle diameter, then fixed with an organic acid (e.g. citric acid or acetic acid), colored, separated, washed with water and dried to give colored powder. The amount of the powder blended is 1-70wt.% preferably 5-50wt.% based on total weight of cosmetic components. The color tone of the colored powder can be controlled by acetylation degree of cellulose acetate and pH of the solution in adsorption, color tone of orange is obtained at 40-54% acetylation degree, color tone of pink - reddish purple at 55-63% acetylation degree when the pH of the solution is fixed. The power can be adjusted to pink - orange by changing pH.
PROBLEM TO BE SOLVED: To obtain a safe and stabilized preventive and therapeutic agent for circulatory system diseases for example hyperlipemia or arteriosclerosis by using a specific derivative prepared by treating alginic acid or its salt with cell bodies of a specific microorganism as an active ingredient. SOLUTION: This preventive and therapeutic agent contains an alginic oligosaccharide or its salt of formula I [R is H, metal ion; R&#39; is G, M, G-G, M-G, M-M, G-G-G, G-G-M, G-M-G (M is D-mannuronic acid of formula II; G is L-gluronic acid of formula III; the bonds between individual monosaccharides are α- or β-1,4-bonds)]. The compound of formula I is obtained by treating alginic acid or its salt with cell bodies of a microorganism in Alteromonas or their treated product. A microorganism in Alteromonas is, for example, Alteromonas sp. No.1786. The alginic oligosaccharide or its salt may be used singly or in any combination of them.
PURPOSE: To prepare a cosmetic capable of preventing the skin from drying up without causing glitteriness, stickiness, messy makeup, etc., of the skin and imparting the moistness to the skin by blending a cosmetic containing a specific amount of a powder with a specified glycoside. CONSTITUTION: This cosmetic is obtained by blending a cosmetic (e.g. a makeup cosmetic) containing &gt;=2wt.% powder (e.g., talc or titanium dioxide) with a glycoside of a hydroxysalicylic acid and/or an aliphatic ester glycoside of the hydroxysalicylic acid of formula I, II or III [R1 is H or a 1-20C (un)saturated hydrocarbon; R2 is a saccharide residue]. The glycoside is preferably blended in an amount of 0.1-20wt.% based on the total amount of the cosmetic. The glycoside is preferably obtained by reacting the hydroxysalicylic acid or its aliphatic ester with an acetylated or an acetobrominated saccharide in the presence of an acidic catalyst. For example, 3-β-D-glucopyranosyloxysalicylic acid is cited as the ingredient (B).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine procurement supporting system capable of quickly procuring medicines without newly placing an order to a wholesale supplier and causing delay in procurement of medicines, even if the medicines which are not in stock are required in a dispensing pharmacy.  &lt;P&gt;SOLUTION: A terminal device 13 transmits sales history information to a management server apparatus 11. The management server apparatus 11 records the sales history information transmitted from each terminal device 13 in a database function 111. A user accesses the management server apparatus 11 from the terminal device 13 through the Internet, and enters medicine information to be retrieved in a medicine retrieval screen and depresses a retrieval button. Then, the management server apparatus 11 retrieves the sales history information, and infers the dispensing pharmacies where the medicines can be procured. Thus, a list of the dispensing pharmacies are displayed at the terminal device 13. The user makes a procurement request to the dispensing pharmacy where the required medicines can be procured from the list of the dispensing pharmacies where the medicines can be procured.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI